China CDE Announces New Clinical Trial Exemption Policies for Imported Innovative New Drugs and Improved Drugs
On April 30, 2020, China NMPA and CDE have issued a number of draft policies for public review relating to China drug registration. The policies announced have obviously favorable benefits for clinical needed overseas innovative new drugs, improved drugs, traditional Chinese medicine compound preparations and high-end generic drugs. And a series of improved procedures make…